AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

Go back to AMGEN TO ACQUIRE CHEMOCENTRYX FOR $4 BILLION IN CASH

Morgan Stanley on Amgen (AMGN): 'We believe the acquisition will be viewed as a modest positive'

August 4, 2022 10:03 AM UTC

Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $253.00 price target on Amgen (NASDAQ: AMGN).

The analyst comments "We believe the acquisition will be viewed as a modest positive given investors are looking for mgt. to expand the pipeline and near-term revenues.... More

ChemoCentryx (CCXI) to Resume Trading at 8:30 a.m.

August 4, 2022 8:07 AM UTC

ChemoCentryx (NASDAQ: CCXI) to Resume Trading at 8:30 a.m.

... More